ArticleThe Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians2026
Impact of Nonmedical Adalimumab Switches in a Rheumatology Patient Population.
Article in The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adalimumab is an antitumor necrosis factor agent approved by the U.S. Food and Drug Administration in 2002 for the treatment of various rheumatologic diseases. Recent approval of adalimumab biosimilars presents an important area of study to determine real-world efficacy and cost savings of biosimilars. Objectives: The primary objective was to evaluate the impact of nonmedical, insurance-mandated adalimumab switches on disease activity. The secondary objective was to assess the financial impact of these biosimilar switches. Methods: A retrospective cohort study was conducted of patients with rheumatic diseases who experienced payer-mandated switches to biosimilars. The primary outcome was change in disease activity, defined by provider assessment documented in the electronic health record before switching and at follow-up. Analyses were completed using chi-square or Fisher exact tests for categorical variables and Results: A total of 152 patients were included; among patients controlled at baseline, 84/119 (70.6%) remained unchanged and 35/119 (29.4%) worsened. Among those partially controlled at baseline, 6/17 (35.3%) improved, 7/17 (41.2%) remained unchanged, and 4/17 (23.5%) worsened. Among patients with active disease at baseline, 9/12 (75.0%) improved and 3/12 (25.0%) remained unchanged. Median out-of-pocket copay change was $0. Conclusion: Insurance-mandated switches did not appear to meaningfully impact disease control for most patients. In addition, median out-of-pocket costs did not change after switching. These findings should reassure pharmacists when helping patients with insurance-mandated adalimumab biosimilar switches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.